Drug intelligence / Profile preview

Lu AF21934

Development stage: Preclinical
Lead developer: Lundbeck
Modality: Small Molecules
Administration: Subcutaneous

Overview

Lu AF21934 is a selective, brain-penetrant small molecule that acts as a positive allosteric modulator (PAM) of the metabotropic glutamate receptor 4 (mGlu4). Developed by Lundbeck, the compound has been investigated in preclinical models for its potential therapeutic effects in anxiety disorders, schizophrenia, and Parkinson's disease. It has demonstrated anxiolytic-like activity in rodent models, a process that appears to involve 5-HT1A receptor signaling, though it lacks antidepressant-like effects. As of current research, Lu AF21934 remains in the preclinical stage of development and has not progressed to human clinical trials.

Targets

HTR2B (5-Hydroxytryptamine Receptor 2B)ADORA2A (Adenosine A₂A Receptor)GRM6 (mGluR6)GRM4 (mGluR4)

Beyond the preview

Go deeper on Lu AF21934.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lu AF21934.

Explore the full profile